title: [Renaissance of thalidomide].
abstract: Thalidomide comes back forty years after the discovery of its teratogenicity. Due to its antiangiogenic and immunomodulating properties, thalidomide is proposed in the treatment of multiple myeloma but also in the management of erythema nodosus leprosis, cutaneous lupus erythematosus and severe aphtosis.
authors.affiliation: Institut de Pharmacie, U.L.B.
authors.forename: F
authors.initials: F
authors.lastname: Waelput
authors.forename: W
authors.initials: W
authors.lastname: Feremans
authors.forename: M
authors.initials: M
authors.lastname: Heenen
authors.forename: J
authors.initials: J
authors.lastname: Sternon
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*; D012871:Skin Diseases / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide